KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Common Equity (2016 - 2025)

Historic Common Equity for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $1.3 billion.

  • Sarepta Therapeutics' Common Equity rose 811.16% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 811.16%. This contributed to the annual value of $1.5 billion for FY2024, which is 7778.15% up from last year.
  • As of Q3 2025, Sarepta Therapeutics' Common Equity stood at $1.3 billion, which was up 811.16% from $1.4 billion recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Common Equity peaked at $1.5 billion during Q4 2024, and registered a low of $385.0 million during Q4 2022.
  • Moreover, its 5-year median value for Common Equity was $856.9 million (2022), whereas its average is $868.5 million.
  • Per our database at Business Quant, Sarepta Therapeutics' Common Equity plummeted by 5851.87% in 2022 and then surged by 12323.34% in 2023.
  • Sarepta Therapeutics' Common Equity (Quarter) stood at $928.0 million in 2021, then plummeted by 58.52% to $385.0 million in 2022, then skyrocketed by 123.23% to $859.3 million in 2023, then surged by 77.78% to $1.5 billion in 2024, then dropped by 13.59% to $1.3 billion in 2025.
  • Its Common Equity stands at $1.3 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.1 billion for Q1 2025.